0
Signin
countryflagUS

18889881171

MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%

Enzolytics Inc

Healthcare US ENZC

0.002USD
0.0001(5.26%)

Last update at 2024-07-25T15:26:00Z

Day Range

0.00180.002
LowHigh

52 Week Range

0.010.13
LowHigh

Fundamentals

  • Previous Close 0.0019
  • Market Cap71.58M
  • Volume1805100
  • P/E Ratio-
  • Dividend Yield8.05%
  • EBITDA-0.88677M
  • Revenue TTM0.05M
  • Revenue Per Share TTM0.22
  • Gross Profit TTM 0.05M
  • Diluted EPS TTM-34.0

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2017-12-31 2016-12-31 2015-12-31 2014-12-31 2011-12-31
Type yearly yearly yearly yearly yearly
Date 2017-12-31 2016-12-31 2015-12-31 2014-12-31 2011-12-31
Income before tax -0.05728M -0.55337M -5.06732M -1.05938M -0.88293M
Minority interest - - - - 0.00000M
Net income -0.05728M -0.54959M -5.04804M -1.07734M -0.88293M
Selling general administrative 0.55M 0.05M 5.02M 0.24M 0.63M
Selling and marketing expenses - - - - -
Gross profit 0.06M 0.00000M 0.00000M 0.00000M 0.05M
Reconciled depreciation - - - - -
Ebit 0.00445M -0.53146M -5.04270M -1.01805M -0.58643M
Ebitda - - - - -
Depreciation and amortization - - - - -
Non operating income net other - - - - 0.00000M
Operating income -0.81601M -0.06404M -5.04270M -0.24446M -0.58643M
Other operating expenses 0.32M 0.02M 0.02M 0.00558M 0.00000M
Interest expense 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total revenue 0.19M 0.00000M 0.00000M 0.00000M 0.05M
Total operating expenses 0.00000M 0.00000M 0.00000M 0.00000M 0.64M
Cost of revenue 0.13M 0.00000M 0.00000M 0.00000M 0.00000M
Total other income expense net 0.82M -0.46742M -0.46742M -0.77359M -0.29650M
Discontinued operations - 0.00378M 0.02M -0.01796M 0.00000M
Net income from continuing ops -0.05728M -0.55337M -5.06732M -1.05938M -0.88293M
Net income applicable to common shares -0.05728M -0.54959M -5.04804M -1.07734M -0.88293M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2017-12-31 2016-12-31 2015-12-31 2014-12-31 2011-12-31
Type yearly yearly yearly yearly yearly
Date 2017-12-31 2016-12-31 2015-12-31 2014-12-31 2011-12-31
Total assets 3.31M 0.06M 0.64M 0.13M 0.03M
Intangible assets - - - - 0.00533M
Earning assets - - - - -
Other current assets - - 0.00054M - 0.00000M
Total liab 7.15M 1.70M 1.71M 1.68M 1.03M
Total stockholder equity -3.84578M -1.64342M -1.06982M -1.55259M -0.99857M
Deferred long term liab - - - - 0.00000M
Other current liab 0.49M 0.49M 0.49M 0.49M 0.55M
Common stock 0.01M 0.01M 0.01M 0.00206M 0.00619M
Capital stock - - - - -
Retained earnings -19.93695M -15.87952M -15.32993M -10.28189M -8.06917M
Other liab - - - - 0.00000M
Good will 3.25M - - - 0.00000M
Other assets - - - - 0.00000M
Cash 0.00013M - 0.01M 0.00004M 0.00808M
Cash and equivalents - - - - -
Total current liabilities 6.31M 1.70M 1.71M 1.68M 0.94M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt 0.38M 0.30M 0.24M 0.24M 0.00000M
Short long term debt 0.38M 0.30M 0.24M 0.24M 0.02M
Short long term debt total - - - - -
Other stockholder equity 0.06M - - - 0.00000M
Property plant equipment 0.06M 0.06M 0.07M 0.09M 0.01M
Total current assets 0.00013M - 0.12M 0.04M 0.00936M
Long term investments - - 0.45M - 0.00000M
Net tangible assets -7.09805M -1.64342M -1.06982M -1.55259M -1.00390M
Short term investments - - - - 0.00000M
Net receivables - 0.04M 0.04M 0.04M 0.00128M
Long term debt - - - - 0.08M
Inventory - - 0.06M - 0.00000M
Accounts payable 5.45M 0.92M 0.99M 0.96M 0.14M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income - - - - 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other - - - - 0.00000M
Deferred long term asset charges - - - - 0.00000M
Non current assets total - - - - 0.00000M
Capital lease obligations - - - - 0.00000M
Long term debt total - - - - 0.00000M
Breakdown 2017-12-31 2016-12-31 2015-12-31 2014-12-31 2011-12-31
Type yearly yearly yearly yearly yearly
Date 2017-12-31 2016-12-31 2015-12-31 2014-12-31 2011-12-31
Investments -4.94088M 0.45M -0.01299M -0.01299M 0.00000M
Change to liabilities 3.80M -0.02729M 0.21M 0.30M -0.01503M
Total cashflows from investing activities -4.95938M 0.45M -0.01404M -0.01404M 0.00000M
Net borrowings 0.07M 0.01M 0.01M 0.10M 0.69M
Total cash from financing activities 0.07M -0.00900M 0.01M 0.02M 0.69M
Change to operating activities - - - - 0.10M
Net income -0.05728M -0.54959M -5.04804M -1.07734M -0.88293M
Change in cash 0.00013M -0.01170M 0.01M -0.00604M 0.00679M
Begin period cash flow - - - - 0.00129M
End period cash flow - - - - -
Total cash from operating activities 4.89M -0.45378M 0.01M -0.02162M -0.68050M
Issuance of capital stock - - - - -
Depreciation 0.32M 0.02M 0.02M 0.00558M 0.00974M
Other cashflows from investing activities - - - - 0.00000M
Dividends paid - - - - 0.00000M
Change to inventory - 0.06M -0.06221M -0.06221M 0.00000M
Change to account receivables - 0.00585M -0.00585M -0.03629M 0.00153M
Sale purchase of stock - -0.02400M -0.02400M -0.07500M 0.00000M
Other cashflows from financing activities - - -0.00054M -0.00700M 0.00000M
Change to netincome 0.82M 0.04M 4.90M 0.79M 0.11M
Capital expenditures 0.02M 0.02M 0.00105M 0.00105M 0.00000M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital - - - - -
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow - - - - -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ENZC
Enzolytics Inc		 0.0001 5.26% 0.002 - - 1536.27 - 1553.31 -11.1243
NVO
Novo Nordisk A/S		 -2.29 1.74% 129.31 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 3.80 2.90% 135.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.67 0.75% 494.48 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 22.92 2.16% 1083.78 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Enzolytics Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company's proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.

Enzolytics Inc

2000 North Central Expressway, Plano, TX, United States, 75074

Key Executives

Name Title Year Born
Mr. Charles S. Cotropia CEO, Pres & Director NA
Dr. Gaurav Chandra M.D. COO & Director NA
Mr. Harry H. Zhabilov Jr. CSO & Director 1967
Dr. Joseph P. Cotropia M.D. Chief Medical Officer & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.